HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SILO

SILO Pharma Inc

Last Close
Dec 13 • 04:00PM ET
0.8351
Dollar change
-0.0869
Percentage change
-9.43 		%
Healthcare • Biotechnology • USA • NASD
Peers: CMPS ATAI MNMD CYCN AVXL GHRS RLMD NERV MNOV RLX
 | Held by: VXF
Scroll to Statements
Index- P/E- EPS (ttm)-1.19 Insider Own4.25% Shs Outstand4.48M Perf Week-9.62%
Market Cap3.39M Forward P/E- EPS next Y- Insider Trans2.99% Shs Float4.29M Perf Month-24.08%
Income-3.78M PEG- EPS next Q- Inst Own7.53% Short Float3.97% Perf Quarter-23.74%
Sales0.07M P/S48.39 EPS this Y- Inst Trans- Short Ratio0.64 Perf Half Y-24.08%
Book/sh1.51 P/B0.55 EPS next Y- ROA-42.31% Short Interest0.17M Perf Year-39.92%
Cash/sh1.98 P/C0.42 EPS next 5Y- ROE-52.02% 52W Range0.77 - 4.50 Perf YTD-42.01%
Dividend Est.- P/FCF- EPS past 5Y-4.01% ROI-55.78% 52W High-81.44% Beta-
Dividend TTM- Quick Ratio7.91 Sales past 5Y-19.76% Gross Margin-844.89% 52W Low8.45% ATR (14)0.10
Dividend Ex-Date- Current Ratio7.91 EPS Y/Y TTM11.90% Oper. Margin-5625.46% RSI (14)35.92 Volatility8.26% 10.67%
Employees3 Debt/Eq0.00 Sales Y/Y TTM0.00% Profit Margin-5247.34% Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-1.65% Payout- Rel Volume0.66 Prev Close0.92
Sales Surprise0.00% EPS Surprise0.00% Sales Q/Q0.00% Earnings- Avg Volume265.96K Price0.84
SMA20-11.53% SMA50-21.18% SMA200-42.22% Trades Volume174,352 Change-9.43%
Nov-29-24 08:05AM
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
(GlobeNewswire) +11.11%
Nov-18-24 08:40AM
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
(GlobeNewswire) -12.39%
Oct-31-24 08:35AM
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
(GlobeNewswire)
Sep-10-24 06:35AM
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
(GlobeNewswire) -13.01%
Aug-14-24 02:30PM
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
(GlobeNewswire) +9.60%
08:13AM Loading…
Aug-07-24 08:13AM
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
(GlobeNewswire) -13.24%
Jul-26-24 08:20AM
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
(GlobeNewswire) +9.95%
Jul-22-24 04:45PM
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
(GlobeNewswire)
Jul-19-24 08:01AM
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
(GlobeNewswire) -29.11%
Jul-18-24 08:25AM
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
(GlobeNewswire) +54.22%
Jul-16-24 08:00AM
Why Is Silo Pharma (SILO) Stock Up 123% Today?
(InvestorPlace) +123.36%
07:43AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
(InvestorPlace)
06:30AM
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
(GlobeNewswire)
Jul-08-24 08:45AM
Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
(GlobeNewswire) -5.19%
Jun-26-24 08:50AM
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
(GlobeNewswire) -6.48%
08:18AM Loading…
Jun-07-24 08:18AM
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
(GlobeNewswire)
Jun-06-24 04:50PM
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
(GlobeNewswire)
Jun-05-24 08:00AM
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
(GlobeNewswire) -46.67%
Jun-04-24 08:41AM
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
(GlobeNewswire) +10.84%
May-21-24 08:45AM
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
(GlobeNewswire) +7.39%
May-14-24 08:45AM
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
(GlobeNewswire)
Apr-23-24 08:15AM
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
(GlobeNewswire) -10.55%
Apr-14-24 03:00PM
10 Micro-Cap Healthcare Stocks Insiders Are Buying
(Insider Monkey)
Apr-10-24 08:11AM
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic
(GlobeNewswire)
Apr-02-24 03:12PM
Hedge Fund and Insider Trading News: Ray Dalio, Steven Tananbaum, Steve Cohen, Crispin Odey, Ken Griffin, Third Point LLC, Westlake Chemical Partners LP (WLKP), and More
(Insider Monkey)
Mar-20-24 08:30AM
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
(GlobeNewswire)
Mar-18-24 07:15AM
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
(GlobeNewswire)
Feb-28-24 08:25AM
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
(GlobeNewswire)
Feb-14-24 08:45AM
Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
(GlobeNewswire) +5.62%
Feb-01-24 10:00AM
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
(GlobeNewswire)
08:55AM Loading…
Jan-24-24 08:55AM
Silo Pharma Announces Positive Results in Alzheimer's Disease Study
(GlobeNewswire) +5.71%
Jan-04-24 08:55AM
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
(GlobeNewswire)
Dec-28-23 08:25AM
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
(GlobeNewswire) -11.00%
Nov-21-23 08:01AM
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
(GlobeNewswire) +12.93%
Nov-08-23 08:11AM
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
(GlobeNewswire)
Oct-16-23 08:11AM
Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
(GlobeNewswire) -7.28%
Oct-11-23 08:35AM
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
(GlobeNewswire)
Sep-20-23 08:28AM
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
(GlobeNewswire)
Sep-12-23 08:50AM
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
(GlobeNewswire)
Aug-10-23 08:50AM
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
(GlobeNewswire)
Aug-08-23 08:30AM
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
(GlobeNewswire)
Jun-23-23 09:00AM
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
(ACCESSWIRE)
Jun-21-23 09:00AM
Silo Pharmas SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
(GlobeNewswire)
Jun-13-23 08:05AM
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
(GlobeNewswire) -5.25%
Jun-02-23 08:50AM
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
(GlobeNewswire)
May-30-23 09:00AM
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
(GlobeNewswire)
May-09-23 08:05AM
Silo Pharmas SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimers Disease
(GlobeNewswire)
Apr-24-23 08:15AM
Silo Pharma to Present at Psychedelic Drug Development Conference
(GlobeNewswire)
Apr-19-23 09:00AM
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
(GlobeNewswire)
Mar-27-23 09:00AM
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
(GlobeNewswire)
Mar-15-23 08:40AM
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
(GlobeNewswire) -5.45%
Feb-13-23 08:35AM
Silo Pharma Announces Filing of Patent for Treatment of Alzheimers
(GlobeNewswire) +14.86%
Feb-02-23 08:50AM
Silo Pharma Announces Expansion of Intellectual Property Portfolio
(GlobeNewswire) +16.35%
Jan-31-23 07:45AM
Silo Pharma Announces Stock Repurchase Program
(GlobeNewswire) +6.37%
Jan-10-23 10:15AM
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
(GlobeNewswire)
Dec-30-22 08:10AM
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
(GlobeNewswire)
Dec-01-22 09:00AM
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
(GlobeNewswire)
Nov-21-22 07:45AM
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
(GlobeNewswire)
Nov-11-22 08:15AM
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
(GlobeNewswire) +6.75%
Oct-26-22 09:00AM
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
(GlobeNewswire)
Oct-20-22 08:05AM
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimers Disease in Pre-Clinical Study
(GlobeNewswire) -12.97%
Oct-18-22 07:15AM
Silo Pharma extends research pact for Alzheimers and Stress Induced Anxiety Therapeutics
(GlobeNewswire)
Oct-10-22 08:05AM
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
(GlobeNewswire)
Oct-06-22 08:20AM
Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12
(GlobeNewswire)
Oct-03-22 09:47AM
Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology
(GlobeNewswire)
Sep-30-22 08:30AM
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriters Over-Allotment Option
(GlobeNewswire)
Sep-27-22 09:05AM
Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock
(GlobeNewswire) -24.56%
Sep-15-22 08:00AM
Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
(GlobeNewswire)
Jul-27-22 08:15AM
Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
(GlobeNewswire)
Jul-12-22 11:23AM
Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients
(GlobeNewswire) +14.90%
Jun-23-22 08:05AM
Silo Pharma Expands License Agreement and Patent Portfolio
(GlobeNewswire) -14.29%
May-19-22 08:11AM
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinsons Disease in Psilocybin Study
(GlobeNewswire)
May-18-22 08:17AM
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
(GlobeNewswire)
Apr-20-22 08:10AM
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study
(GlobeNewswire) +6.45%
Mar-31-22 08:10AM
Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study
(GlobeNewswire)
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weisblum EricCEO and PresidentNov 20 '24Buy0.952,5002,375182,932Nov 22 04:16 PM
Weisblum EricCEO and PresidentNov 22 '24Buy0.902,5002,250185,432Nov 22 04:16 PM
Weisblum EricCEO and PresidentJun 12 '24Buy1.114,4384,926180,432Jun 13 01:19 PM
Weisblum EricCEO and PresidentJun 11 '24Buy1.08562607175,994Jun 13 01:19 PM
Weisblum EricCEO and PresidentApr 04 '24Buy1.966001,176175,032Apr 08 04:00 PM
Weisblum EricCEO and PresidentApr 05 '24Buy2.03400812175,432Apr 08 04:00 PM
Weisblum EricCEO and PresidentMar 28 '24Buy1.943,4086,612173,332Apr 01 06:15 PM
Weisblum EricCEO and PresidentApr 01 '24Buy1.911,1002,101174,432Apr 01 06:15 PM
Weisblum EricCEO and PresidentDec 19 '23Buy1.63500815169,724Dec 21 04:13 PM
Weisblum EricCEO and PresidentDec 20 '23Buy1.61200322169,924Dec 21 04:13 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.